What’s new

• Promoter Sudhir Sethi bought 6,950 shares on 25 June 2026 via open market, crossing the 10% ownership threshold.
• His stake rose from 9.915% to 10.055%, a net increase of 0.14% of equity.
• The acquisition value is about 1.37% of the company's ₹12 cr market cap, passing the nano-cap materiality mark.

Why it matters

Crossing 10% triggers disclosure under SEBI Takeover Regulations and signals the promoter is willing to increase skin in the game. For a ₹12 cr nano-cap with thin trading, even a small purchase can be meaningful, though the absolute quantum limits the likely price impact.

What we’re watching

• Whether Sethi continues the incremental buying pattern seen in recent weeks.
• Any reaction in the thinly traded stock over the next few sessions.
• Upcoming quarterly results for signs of operational improvement.

The full read

Beryl Drugs promoter Sudhir Sethi bought 6,950 shares on June 25, lifting his stake from 9.915% to 10.055% of the 50,71,700 equity shares. The acquisition, worth about 1.37% of the ₹12 cr market cap, crosses the 10% threshold under SEBI Takeover Regulations. The increase is tiny — just 0.14% of equity. It follows a pattern of incremental buying. Still, for a stock with thin liquidity, it is a modest vote of confidence from a promoter who could have deployed capital elsewhere. The absolute quantum limits price impact, but the signal is what matters.

Primary source: BSE · NSE